文献速递垂体与肾上腺疾病肥胖与代谢综合征

基于人群的无功能肾上腺腺瘤患者心血管代谢结局与死亡率

Cardiometabolic Outcomes and Mortality in Patients with Adrenal Adenomas in a Population-based Setting.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该基于人群的队列研究纳入1995至2017年诊断的无明显激素过剩的肾上腺腺瘤患者1004例及年龄性别匹配的参照者。基线时患者高血压、血糖异常、外周血管疾病、心力衰竭和心肌梗死患病率更高,随访中慢性肾病、心律失常、外周血管疾病、心血管事件和静脉血栓栓塞发生率增加,但调整后死亡率两组相似。

要点

  • 肾上腺腺瘤患者基线高血压风险显著升高(aOR 1.96, 95%CI 1.58-2.44)。
  • 随访期间静脉血栓栓塞事件风险增加(aHR 2.15, 95%CI 1.48-3.13)。
  • 调整后死亡率与无腺瘤参照者无显著差异。

核心结论

  • 在基于人群的队列中,无功能肾上腺腺瘤与多种心血管代谢不良结局的患病率和发病率增加相关。

研究设计与样本

  • 基于人群的队列研究,纳入美国明尼苏达州奥姆斯特德县1995年1月1日至2017年12月31日诊断的1004例无功能肾上腺腺瘤患者(58%女性,中位年龄63岁)及年龄性别匹配的参照者。

主要发现

  • 基线时肾上腺腺瘤患者高血压患病风险升高(aOR 1.96, 95%CI 1.58-2.44)。
  • 基线时血糖异常(aOR 1.63, 95%CI 1.33-2.00)、外周血管疾病(aOR 1.59, 95%CI 1.32-2.06)、心力衰竭(aOR 1.64, 95%CI 1.15-2.33)和心肌梗死(aOR 1.50, 95%CI 1.02-2.22)风险升高。
  • 中位随访6.8年期间,新发慢性肾病(aHR 1.46, 95%CI 1.14-1.86)、心律失常(aHR 1.31, 95%CI 1.08-1.58)、外周血管疾病(aHR 1.28, 95%CI 1.05-1.55)、心血管事件(aHR 1.33, 95%CI 1.01-1.73)和静脉血栓栓塞事件(aHR 2.15, 95%CI 1.48-3.13)风险增加。
  • 调整后死亡率两组相似。

临床怎么用

  • 对无功能肾上腺腺瘤患者应关注并筛查高血压、血糖异常及心血管疾病。
  • 随访中需警惕慢性肾病、心律失常、外周血管疾病、心血管事件及静脉血栓栓塞事件的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: While adrenal adenomas have been linked with cardiovascular morbidity in convenience samples of patients from specialized referral centers, large-scale population-based data are lacking. OBJECTIVE: To determine the prevalence and incidence of cardiometabolic disease and assess mortality in a population-based cohort of patients with adrenal adenomas. DESIGN: Population-based cohort study. SETTING: Olmsted County, Minnesota, USA. PATIENTS: Patients diagnosed with adrenal adenomas without overt hormone excess and age- and sex-matched referent subjects without adrenal adenomas. MAIN OUTCOME MEASURE: Prevalence, incidence of cardiometabolic outcomes, mortality. RESULTS: (Adrenal adenomas were diagnosed in 1004 patients (58% women, median age 63 years) from 1/01/1995 to 12/31/2017. At baseline, patients with adrenal adenomas were more likely to have hypertension [adjusted odds ratio (aOR) 1.96, 95% CI 1.58-2.44], dysglycemia (aOR 1.63, 95% CI 1.33-2.00), peripheral vascular disease (aOR 1.59, 95% CI 1.32-2.06), heart failure (aOR 1.64, 95% CI 1.15-2.33), and myocardial infarction (aOR 1.50, 95% CI 1.02-2.22) compared to referent subjects. During median follow-up of 6.8 years, patients with adrenal adenomas were more likely than referent subjects to develop de novo chronic kidney disease [adjusted hazard ratio (aHR) 1.46, 95% CI 1.14-1.86], cardiac arrhythmia (aHR 1.31, 95% CI 1.08-1.58), peripheral vascular disease (aHR 1.28, 95% CI 1.05-1.55), cardiovascular events (aHR 1.33, 95% CI 1.01-1.73), and venous thromboembolic events (aHR 2.15, 95% CI 1.48-3.13). Adjusted mortality was similar between the 2 groups. CONCLUSION: Adrenal adenomas are associated with an increased prevalence and incidence of adverse cardiometabolic outcomes in a population-based cohort.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zhang CD, Li D, Kaur RJ, et al. Cardiometabolic Outcomes and Mortality in Patients with Adrenal Adenomas in a Population-based Setting. J Clin Endocrinol Metab. 2021. PMID: 34185830. doi:10.1210/clinem/dgab468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。